Leidos answers the in-sourcing question — with munitions and a bridge across the VA

Leidos' second-quarter print (reported Aug 4) was, on its face, a beat-and-raise: record revenue of $4.6 billion, up 7% year-over-year, a Q2 record ~$800 million of operating cash flow, and the midpoint of revenue, EPS and cash guidance all lifted. But beneath the headline sits the real story — a pair of structural questions the market has been de-rating the company over, now crystallized on the call: whether the government's in-sourcing push makes systems integrators obsolete (the MHS GENESIS pivot), and what the VA medical-exam recompete actually looks like once incentive payments go away. Management's answer is characteristically single-minded: lean into where the customer is going, and offset the managed-health margin reset with a defense-hardware ramp.

The systems-integrator model gets a stress test

The clearest "what changed" of the quarter is MHS GENESIS. Under the original 10-year contract Leidos built the DoD's EHR — on time and under budget, Tom Bell is careful to note — but now the Defense Health Agency is considering doing the systems integration itself and procuring software directly from commercial vendors. Bell frames it as a generalized trend:

I think, honestly, the trend here is that there is an interest in in-sourcing across many government agencies right now. What they're interested in in-sourcing is the systems integration, as you say, but also the acquisition of commercial technology per the aspirations of this administration. So we see that trend continuing across many agencies.

This is the same question investors have pushed on before — the Aug 2025 call opened with an analyst asking about the GSA buying software directly from vendors rather than through integrators. Bell's answer then was buoyant: “we see ourselves as what the GSA is looking for more of, not less of.” — Thomas A. Bell, Chief Executive Officer · 2025-08-05 What's new now is that the abstraction has become a live, named program: Leidos will "continue to support and enhance MHS GENESIS under a sole-source bridge contract," while conceding the role of the integrator is being renegotiated agency by agency. The pivot — into what Bell calls "higher-level mission systems integration capabilities" — is credible, but it is also a quiet acknowledgement that a chunk of the value chain is going away.

VBA: the draft RFP finally lands in view

The other overhang was the VA. The call added genuine draft RFP specificity that prior quarters lacked — for three straight prior calls the answer was "industry day this summer," "we'll know more soon." Now the VA has suspended incentive payments for all vendors for the rest of the year, and Leidos has priced that into guidance: “those changes for this year are fully enveloped in our improved guidance for 2026.” — Thomas Bell, Chief Executive Officer · 2026-08-04 The timing is also clearer: “we expect the draft RFP any day. And then we hope that, that will turn into a formal RFP, let's call it, 30, 45, 60 days later.” — Thomas Bell, Chief Executive Officer · 2026-08-04

The framing is telling — management wants the market to anchor on Q4's run-rate as "probably a good jumping off point for what we're looking at for 2027," and is leaning on the fact that the VA will likely extend the current regions contract up to six months while international and predischarge work gets a year-long extension. The health platform itself is being repositioned around Behavioral Health and rural health rather than exam volume alone — reusing the same muscle that had cut the veteran exam backlog ~60% on prior calls (“we have got a fantastic machine there that has helped our customer decrease backlog of veterans awaiting exams by almost 60%.” — Thomas A. Bell, Chief Executive Officer (CEO) · 2026-02-17). The difference this quarter is that incentive payments — a real income line — are gone for 2026, and the margin question is now a 2027 question.

Defense tech: from exquisite to industrial

The offset is defense. Defense booked a 2.2 book-to-bill in Q2 (1.9 trailing twelve months), and management expanded the "defense tech" growth engines from space and maritime to include munitions and counter-UAS. The flagship is the low-cost containerized munitions framework — “the addressable markets that we're talking about here just for low-cost and containerized munitions is in excess of $44 billion over the next 10 years” — Thomas Bell, Chief Executive Officer · 2026-08-04 — plus Golden Dome sensor payloads (18 more satellites), the Navy's medium unmanned surface vessel (a possible production award in Q4), and counter-UAS hardware. Margin trajectory is part of the pitch: each of these programs matures at higher profitability, with “more quantities, more maturity... the margins in that part of the business really accelerating.” — Chris Cage, Chief Financial Officer · 2026-08-04 Chris Cage's prepared frame was the cleanest: with the VBA headwinds layered in, "the rest of Leidos to grow approximately 7% in revenues and 19% in adjusted EBITDA in 2026."

Away from the wave

The market's own keyword stream is dominated by tariff refunds and data-center demand — IEEPA refund and Batch Zero top the global list for 20263. Leidos' call is conspicuously silent on both; its concerns are entirely its own (recompete, in-sourcing, munitions). That independence cuts both ways. The 90-day tape tells the story: the stock fell ~30% into mid-April, then bounced ~33% — peak-to-current drawdown still ~11%, and it sits ~30% below its late-2024 high. The de-rating reflects the services-sector fear Leidos is now trying to talk through — while delivering a record quarter of free cash flow ($761M) and lifting cash guidance gives it the balance-sheet room to spend its way forward: $300M of commercial paper paid down, a fresh buyback authorization, CapEx guided down to ~$250M, and the SES JV (with Analogic) still to close. For a company being re-rated as a lower-multiple integrator, the answer — buy back stock, keep capital intensity low, and let the Defense Tech business carry margin expansion — is coherent. Whether the market buys the bridge across the VA is the question the next two quarters will decide.